{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:53:03Z","timestamp":1791438783890,"version":"4.3.3"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019111","name":"Perron Institute for Neurological and Translational Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omtn.2026.102953","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:33:24Z","timestamp":1778762004000},"page":"102953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expanding the toolbox: Emerging antisense oligonucleotide mechanisms for modulating gene expression"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1674-0740","authenticated-orcid":false,"given":"Isabella","family":"Trew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve D.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Cale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-2303","authenticated-orcid":false,"given":"May","family":"Aung-Htut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102953_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102953_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2026.102953_bib3","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2026.102953_bib4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2026.102953_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.102953_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102953_bib7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2026.102953_bib8","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102953_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib12","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide\u2013protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hlca.19950780219","article-title":"Ein neuer Zugang zu 2\u2032-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide","volume":"78","author":"Martin","year":"1995","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.omtn.2026.102953_bib14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic Properties of 2\u2032-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats","volume":"296","author":"Geary","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.omtn.2026.102953_bib15","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated Safety Assessment of 2\u2032-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102953_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The Effects of 2\u2032-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.102953_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","article-title":"Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.omtn.2026.102953_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino Antisense Oligomers: Design, Preparation, and Properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.omtn.2026.102953_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting \u2014 Strategies and applications","volume":"203","author":"D\u2019Souza","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102953_bib20","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500584","article-title":"Toxicity of Antisense Oligonucleotides is Determined by the Synergistic Interplay of Chemical Modifications and Nucleotide Sequences, Not by Either Factor Alone","volume":"26","author":"Bhamra","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.omtn.2026.102953_bib22","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1021\/acs.jmedchem.4c02528","article-title":"Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver","volume":"68","author":"Anand","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2026.102953_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1006\/jmbi.1993.1528","article-title":"Structure of a DNA : RNA Hybrid Duplex: Why RNase H Does Not Cleave Pure RNA","volume":"233","author":"Fedoroff","year":"1993","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omtn.2026.102953_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-0716-0771-8_2","article-title":"Development and Clinical Applications of Antisense Oligonucleotide Gapmers","volume":"2176","author":"Chan","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2026.102953_bib25","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1073\/pnas.85.14.5011","article-title":"Role of RNase H in hybrid-arrested translation by antisense oligonucleotides","volume":"85","author":"Walder","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102953_bib26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib27","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/17512433.2019.1635008","article-title":"Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis","volume":"12","author":"Gertz","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102953_bib30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.omtn.2026.102953_bib32","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2026.102953_bib33","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146090","article-title":"Antisense oligonucleotide therapy for KCNT1 encephalopathy","volume":"7","author":"Burbano","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2026.102953_bib35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102953_bib36","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1038\/s41591-024-03197-y","article-title":"Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder","volume":"30","author":"Ziegler","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0002-9394(02)01326-0","article-title":"Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS","volume":"133","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2026.102953_bib38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102953_bib39","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.omtn.2026.102953_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102246","article-title":"Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT","volume":"35","author":"Iwamoto","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102953_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","article-title":"Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons","volume":"27","author":"Hauser","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102953_bib43","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102953_bib44","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41375-018-0067-3","article-title":"Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity","volume":"32","author":"Amodio","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omtn.2026.102953_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145991","article-title":"Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model","volume":"6","author":"Milazzo","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2026.102953_bib46","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1038\/s41591-025-03784-7","article-title":"The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial","volume":"31","author":"Hipp","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib47","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nsmb.1444","article-title":"Antisense transcripts are targets for activating small RNAs","volume":"15","author":"Schwartz","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omtn.2026.102953_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/nat.2022.0040","article-title":"Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides","volume":"33","author":"L\u00f8vendorf","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.102953_bib49","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1038\/s41598-021-82509-5","article-title":"Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia","volume":"11","author":"Hofmans","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102953_bib50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12885-025-13623-0","article-title":"Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma","volume":"25","author":"Deguchi","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omtn.2026.102953_bib51","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1093\/hmg\/dds130","article-title":"Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a","volume":"21","author":"Meng","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.102953_bib52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature13975","article-title":"Towards a therapy for Angelman syndrome by targeting a long non-coding RNA","volume":"518","author":"Meng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102953_bib53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1172\/JCI13885","article-title":"The experimental use of antisense oligonucleotides: a guide for the perplexed","volume":"108","author":"Stein","year":"2001","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.102953_bib54","doi-asserted-by":"crossref","first-page":"8476","DOI":"10.1093\/nar\/gkv759","article-title":"Dissecting the target specificity of RNase H recruiting oligonucleotides using massively parallel reporter analysis of short RNA motifs","volume":"43","author":"Rukov","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40291-021-00573-z","article-title":"Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension","volume":"26","author":"Yasuhara","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.omtn.2026.102953_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: A review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102953_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, Biogenesis, Mechanism, and Function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.102953_bib58","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","article-title":"Single-Stranded siRNAs Activate RNAi in Animals","volume":"150","author":"Lima","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.102953_bib59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1073\/pnas.75.1.256","article-title":"pppA2\u2019p5\u2019A2\u2019p5\u2019A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells","volume":"75","author":"Kerr","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102953_bib60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1249845","article-title":"Structure of Human RNase L Reveals the Basis for Regulated RNA Decay in the IFN Response","volume":"343","author":"Han","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.102953_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/095632029800900303","article-title":"Targeting RNase L to Human Immunodeficiency Virus RNA with 2-5A-Antisense","volume":"9","author":"Player","year":"1998","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.omtn.2026.102953_bib62","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1002\/ange.202105942","article-title":"Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation","volume":"133","author":"Su","year":"2021","journal-title":"Angew. Chem."},{"key":"10.1016\/j.omtn.2026.102953_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00205-20","article-title":"RNase L Amplifies Interferon Signaling by Inducing Protein Kinase R-Mediated Antiviral Stress Granules","volume":"94","author":"Manivannan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2026.102953_bib64","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1093\/nar\/gkab036","article-title":"Activation of the antiviral factor RNase L triggers translation of non-coding mRNA sequences","volume":"49","author":"Karasik","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib65","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/cdd.2012.23","article-title":"RNase L controls terminal adipocyte differentiation, lipids storage and insulin sensitivity via CHOP10 mRNA regulation","volume":"19","author":"Fabre","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omtn.2026.102953_bib66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nsmb944","article-title":"A newly discovered function for RNase L in regulating translation termination","volume":"12","author":"Roy","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omtn.2026.102953_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4161\/rna.6.3.8526","article-title":"Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence","volume":"6","author":"Andersen","year":"2009","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2026.102953_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng0102-13","article-title":"A genomic view of alternative splicing","volume":"30","author":"Modrek","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2026.102953_bib69","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1074\/jbc.270.6.2411","article-title":"Exon Recognition in Vertebrate Splicing","volume":"270","author":"Berget","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102953_bib70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/wrna.1140","article-title":"Exon and intron definition in pre-mRNA splicing","volume":"4","author":"De Conti","year":"2013","journal-title":"WIREs RNA"},{"key":"10.1016\/j.omtn.2026.102953_bib71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0960-8966(99)00010-3","article-title":"Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides","volume":"9","author":"Wilton","year":"1999","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.102953_bib72","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm897","article-title":"Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse","volume":"9","author":"Lu","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105925","article-title":"291PTREAT-NMD neuromuscular network: variations in DMD mutation distribution in the Duchenne muscular dystrophy dataset","volume":"53","author":"Zito","year":"2025","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.102953_bib74","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense Masking of an hnRNP A1\/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2026.102953_bib75","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtn.2026.102953_bib76","article-title":"Modulators and modulation of the receptor for advanced glycation end-products RNA","author":"Wilton","year":"2023","journal-title":"US Patent 17930364"},{"key":"10.1016\/j.omtn.2026.102953_bib77","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41467-020-17093-9","article-title":"Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression","volume":"11","author":"Lim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102953_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49385-6","article-title":"Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides","volume":"9","author":"Aung-Htut","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102953_bib79","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/hmg\/ddac286","article-title":"Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant","volume":"32","author":"Enkhjargal","year":"2023","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.102953_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105712","article-title":"165PAntisense oligonucleotide NS-035 targeting pathogenic exon-trapping in Fukuyama muscular dystrophy: a phase 1 trial","volume":"53","author":"Fujino","year":"2025","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.102953_bib81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2024.0072","article-title":"Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations","volume":"35","author":"Andersson","year":"2025","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.102953_bib82","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1113\/JP288955","article-title":"Molecular and pharmacological evaluation of rare, cystic fibrosis-causing missense mutations of the CFTR channel","volume":"603","author":"Z\u00e1voti","year":"2025","journal-title":"J. Physiol."},{"key":"10.1016\/j.omtn.2026.102953_bib83","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.102953_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105394","article-title":"Antisense oligonucleotide-mediated redirection of Igf1 alternative polyadenylation","volume":"51","author":"Yavas","year":"2025","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2026.102953_bib85","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jaci.2021.09.039","article-title":"Targeting IgE polyadenylation signal with antisense oligonucleotides decreases IgE secretion and plasma cell viability","volume":"149","author":"Marchalot","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.omtn.2026.102953_bib86","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s00018-020-03632-6","article-title":"NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma","volume":"78","author":"Naveed","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2026.102953_bib87","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1126\/science.abq5622","article-title":"Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies","volume":"379","author":"Baughn","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.102953_bib88","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-024-48963-1","article-title":"Structures of co-transcriptional RNA capping enzymes on paused transcription complex","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102953_bib89","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV Infection by Targeting MicroRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102953_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.331","article-title":"383P Clinical experience with TTX-MC138: A first-in-class therapy against metastatic cancer","volume":"35","author":"Varkaris","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2026.102953_bib91","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","article-title":"miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models","volume":"9","author":"Cerro-Herreros","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102953_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn6525","article-title":"AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action","volume":"10","author":"Cerro-Herreros","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2026.102953_bib93","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/bioinformatics\/btx019","article-title":"miRmine: a database of human miRNA expression profiles","volume":"33","author":"Panwar","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2026.102953_bib94","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature07228","article-title":"Widespread changes in protein synthesis induced by microRNAs","volume":"455","author":"Selbach","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102953_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105475","article-title":"Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation","volume":"299","author":"Aggarwal","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102953_bib96","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1165\/rcmb.2018-0316OC","article-title":"Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR","volume":"61","author":"Keenan","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.omtn.2026.102953_bib97","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","article-title":"CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway","volume":"13","author":"Sanderlin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102953_bib98","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"Lueck","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102953_bib99","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52611","article-title":"Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides","volume":"9","author":"Wangen","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.omtn.2026.102953_bib100","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1093\/nar\/gkae624","article-title":"mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs)","volume":"52","author":"Susorov","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib101","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1128\/AAC.03442-14","article-title":"Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies","volume":"58","author":"Heald","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.omtn.2026.102953_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0020001","article-title":"Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers","volume":"2","author":"Warfield","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtn.2026.102953_bib103","doi-asserted-by":"crossref","first-page":"11669","DOI":"10.1128\/JVI.00557-07","article-title":"Inhibition of Foot-and-Mouth Disease Virus Infections in Cell Cultures with Antisense Morpholino Oligomers","volume":"81","author":"Vagnozzi","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2026.102953_bib104","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1099\/vir.0.83449-0","article-title":"Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus","volume":"89","author":"Gabriel","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omtn.2026.102953_bib105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbrc.2021.10.034","article-title":"Antisense oligonucleotide repress telomerase activity via manipulating alternative splicing or translation","volume":"582","author":"Zhou","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2026.102953_bib106","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1093\/nar\/17.11.4255","article-title":"Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides","volume":"17","author":"Cazenave","year":"1989","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib107","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/nar\/19.5.1113","article-title":"Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism","volume":"19","author":"Boiziau","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib108","doi-asserted-by":"crossref","first-page":"11994","DOI":"10.1074\/jbc.272.18.11994","article-title":"2\u2032-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells","volume":"272","author":"Baker","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102953_bib109","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1073\/pnas.0810916106","article-title":"Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans","volume":"106","author":"Calvo","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.omtn.2026.102953_bib110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nbt.3589","article-title":"Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames","volume":"34","author":"Liang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102953_bib111","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2022060644","article-title":"Translation Rescue by Targeting Ppp1r15a through Its Upstream Open Reading Frame in Sepsis-Induced Acute Kidney Injury in a Murine Model","volume":"34","author":"Kidwell","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.omtn.2026.102953_bib112","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ymthe.2019.06.016","article-title":"Steric Inhibition of 5\u2019 UTR Regulatory Elements Results in Upregulation of Human CFTR","volume":"27","author":"Sasaki","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102953_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162893","article-title":"Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis","volume":"8","author":"Tan","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2026.102953_bib114","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4161\/bioe.27607","article-title":"Engineering ribosomal leaky scanning and upstream open reading frames for precise control of protein translation","volume":"5","author":"Ferreira","year":"2014","journal-title":"Bioengineered"},{"key":"10.1016\/j.omtn.2026.102953_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102406","article-title":"uORF-targeting steric block antisense oligonucleotides do not reproducibly increase RNASEH1 expression","volume":"36","author":"Ahlskog","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102953_bib116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010460","article-title":"Translational buffering by ribosome stalling in upstream open reading frames","volume":"18","author":"Bottorff","year":"2022","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2026.102953_bib117","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/ijms26051979","article-title":"Structural Features of 5\u2032 Untranslated Region in Translational Control of Eukaryotes","volume":"26","author":"Razumova","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.102953_bib118","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1038\/s41467-023-41799-1","article-title":"Secondary structures that regulate mRNA translation provide insights for ASO-mediated modulation of cardiac hypertrophy","volume":"14","author":"Hedaya","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102953_bib119","first-page":"3222","article-title":"Photochemical Cross-Linking of Cap Binding Proteins to Eucaryotic mRNAs: Effect of mRNA 5\u2032 Secondary Structure","volume":"5","author":"Pelletier","year":"1985","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2026.102953_bib120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.nutr.28.061807.155521","article-title":"Systemic Iron Homeostasis and the Iron-Responsive Element\/Iron-Regulatory Protein (IRE\/IRP) Regulatory Network","volume":"28","author":"Muckenthaler","year":"2008","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.omtn.2026.102953_bib121","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1093\/nar\/gkx632","article-title":"Antisense oligonucleotides targeting translation inhibitory elements in 5\u2032 UTRs can selectively increase protein levels","volume":"45","author":"Liang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib122","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1093\/nar\/gkab954","article-title":"Targeting 3\u2019 and 5\u2019 untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression","volume":"49","author":"Li","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102953_bib123","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.omtn.2020.12.027","article-title":"Targeting the 5\u2032 untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy","volume":"23","author":"Winkelsas","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:11:59Z","timestamp":1791436319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2162253126001241"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102953","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the toolbox: Emerging antisense oligonucleotide mechanisms for modulating gene expression","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102953"}}